Inpatient mortality, n (%) | Total | Crude OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value | ||
---|---|---|---|---|---|---|---|
Age | < 60 yrs | 66 (24.1%) | 274 | ||||
> 60 yrs | 88 (44.4%) | 198 | 2.52 (1.70–3.74) | < 0.001 | 2.74 (1.60–4.69) | < 0.001 | |
Vaccine status | Not received | 149 (33.7%) | 442 | ||||
Received at least 1 dose | 5 (16.7%) | 30 | 0.39 (0.15–1.05) | 0.062 | 0.23 (0.07–0.84) | 0.025 | |
Hypertension | No | 89 (27.4%) | 304 | ||||
Yes | 65 (38.0%) | 168 | 1.52 (1.03–2.27) | 0.037 | 1.52 (0.87–2.65) | 0.139 | |
History of Stroke | No | 148 (32.2%) | 460 | ||||
Yes | 6 (50.0%) | 12 | 2.11 (0.67–6.65) | 0.203 | 2.44 (0.47–12.52) | 0.286 | |
Malignancy | No | 148 (31.8%) | 465 | ||||
Yes | 6 (85.7%) | 7 | 12.85 (1.53–107.71) | 0.019 | 19.70 (1.52–255.44) | 0.023 | |
COVID-19 Severity | Severe | 25 (8.9%) | 280 | ||||
Critical | 129 (67.2%) | 192 | 20.56 (12.55–34.76) | < 0.001 | 23.37 (13.45–40.62) | < 0.001 | |
Anticoagulation dosage | Prophylactic | 66 (27.8%) | 237 | ||||
Therapeutic | 88 (37.4%) | 235 | 1.55 (1.05–2.29) | 0.027 | 1.70 (1.02–2.84) | 0.042 |